Tesla shares (TSLA)

Key Updates

Tesla shares recovered 2.10% to $364.34 since the March 30 report, breaking a three-session decline but remaining within the established downtrend. The modest rebound occurs ahead of the critical Q1 delivery report expected to show 365,645 units (+8% YoY), while European sales data confirms the first regional growth in over a year with February registrations up 29% YoY. Despite the technical bounce, YTD losses persist at -18.99%, and fundamental concerns around negative free cash flow projections and massive capital requirements for the Terafab project continue to weigh on the long-term outlook.

Current Trend

Tesla remains in a pronounced downtrend with YTD losses of -18.99% through March 31, marking one of the weakest performance periods in recent years. The stock has declined across all timeframes: -4.88% over 5 days, -9.48% over 1 month, -18.07% over 6 months. The current price of $364.34 represents a modest recovery from the March 30 low of $356.84 but remains below the critical $370 support level broken earlier in the week. The 6-month chart shows a clear pattern of lower highs and lower lows, with the stock failing to sustain any meaningful rallies. Near-term resistance now sits at $370-$380, while the YTD low of $356.84 establishes immediate support.

Investment Thesis

The investment thesis centers on Tesla's transition from an automotive manufacturer to a diversified technology conglomerate focused on autonomous driving, robotics, energy solutions, and semiconductor production. Bank of America's valuation framework assigns 54% of Tesla's value to robotaxi operations ($422 billion) and FSD software ($313 billion), compared to just 21% for the core automotive business ($345 billion). This thesis requires successful execution across multiple fronts: achieving regulatory approval for FSD in Europe and China, scaling robotaxi services from 2 cities to 9+ by year-end, expanding FSD adoption from 1.1 million to 8.7 million customers by 2030, and establishing the Terafab semiconductor facility to meet AI chip demand. The $20+ billion capital expenditure program in 2026 represents the largest investment cycle since 2018, with potential for negative free cash flow as the company funds these transformational initiatives. Success depends on maintaining automotive revenue of $69.5 billion annually to finance these ventures while navigating intensifying EV market competition and potential demand headwinds.

Thesis Status

The investment thesis faces near-term execution risks but maintains structural validity. Positive developments include European sales growth returning after a year-long decline, with February registrations up 29% YoY, and institutional validation from Bank of America's buy rating with $460 price target. However, significant headwinds emerge: projected negative free cash flow of $4.1 billion in 2026 marks the first cash burn since 2018, while Terafab capital requirements could reach $300 billion at full capacity. The upcoming Q1 delivery report showing 8% YoY growth demonstrates automotive business stability but confirms the market's shift in focus toward future technologies rather than current operations. The thesis remains intact but requires flawless execution on autonomous driving commercialization and semiconductor production to justify current valuations.

Key Drivers

Immediate catalyst: Q1 delivery report expected to show 365,645 vehicles (+8% YoY), with investor focus on whether automotive fundamentals can support the massive capital expenditure program. European market recovery: First sales growth in over a year with 13,740 EU registrations in February (+29% YoY), driven by cheaper Model Y and Model 3 variants plus sales incentives. Terafab semiconductor project: Launch in 7 days with initial capex estimated at $30 billion and potential $300 billion for full capacity, targeting AI5 chip production for 2027. Robotaxi expansion: Currently operating in San Francisco and Austin with 7 additional markets expected in H1 2026. Capital allocation concerns: $20+ billion capex in 2026 excluding Terafab could drive first negative FCF since 2018 despite $44 billion cash position at YE 2025.

Technical Analysis

Tesla exhibits a clear downtrend structure with the current price at $364.34 representing a 2.10% recovery from the March 30 low of $356.84. The stock has established a pattern of lower highs throughout Q1 2026, with each rally attempt failing at progressively lower levels. The critical $370 support level, broken on March 27, now serves as near-term resistance, with additional overhead resistance at $380. The YTD decline of -18.99% places TSLA among the weakest performers in large-cap technology, with the 6-month loss of -18.07% confirming sustained selling pressure. The recent 2.10% bounce shows minimal conviction, occurring on the back of European sales data and ahead of the Q1 delivery report. Volume patterns suggest distribution rather than accumulation, with rallies met by consistent selling. The $356.84 level represents immediate support, with a break below potentially targeting the $340-$350 zone. Any sustainable recovery requires reclaiming $370 and holding above this level for multiple sessions.

Bull Case

• Autonomous driving valuation upside: Bank of America values robotaxi and FSD businesses at $735 billion versus $345 billion for EVs, with cost per mile projected at $1.58 versus $3.41 for traditional ride-sharing, representing 54% gross margin potential at scale.
• European market inflection: First sales growth in over a year with February EU registrations up 29% YoY to 13,740 units, driven by lower-priced variants and FSD regulatory approval expected in summer 2025 starting with Netherlands.
• Robotaxi market dominance potential: Wall Street projects Tesla could capture up to 50% of global robotaxi market with Morgan Stanley forecasting 5 million units by 2035, expanding from 2 cities currently to 9 markets by year-end 2026.
• Vertical integration through Terafab: In-house chip production launching in 7 days addresses supply constraints from TSMC, Samsung, and Micron, with AI5 chip targeting volume production in 2027 for competitive advantage in autonomous systems.
• Diversified revenue streams beyond automotive: Optimus humanoid robot segment valued at $30+ billion and energy business at $90 billion provide multiple growth vectors independent of core EV sales performance.

Bear Case

• Negative free cash flow trajectory: Analysts project negative FCF of $4.1 billion in 2026, the first cash burn since 2018, with $20+ billion capex excluding Terafab straining the $44 billion cash position and raising capital allocation concerns.
• Unprecedented capital requirements for Terafab: UBS estimates $30 billion initial investment with potential $300 billion to achieve full production capacity, representing execution risk in an unfamiliar semiconductor manufacturing business with established competitors.
• Automotive revenue dependency persists: EV business generated $69.5 billion in revenue last year—more than double the rest of the company, creating vulnerability as investor focus shifts to unproven future technologies while core business faces margin pressure from incentives.
• Limited FSD adoption undermines robotaxi thesis: Only 1.1 million of 8.9 million vehicles sold have purchased FSD subscriptions, requiring expansion to 8.7 million customers by 2030 plus regulatory approval in China and Europe for valuation models to materialize.
• Technical breakdown confirms bearish sentiment: YTD losses of -18.99% with sustained downtrend across all timeframes (-4.88% 5d, -9.48% 1m, -18.07% 6m) and break below $370 support level signals institutional distribution and waning confidence in near-term catalysts despite ambitious long-term projects.